Log In Sign up
The largest database of trusted experimental protocols

Upadacitinib

Manufactured by MedChemExpress
Visit Supplier
Sourced in United States

Upadacitinib is a laboratory product manufactured by MedChemExpress. It is a selective and reversible Janus kinase (JAK) inhibitor.

Automatically generated - may contain errors

Lab products found in correlation

Baricitinib, by MedChemExpress (2 mentions) Fludarabine, by Cayman Chemical (1 mentions) Cpg dna, by InvivoGen (1 mentions) Lipid a, by Peptide Institute (1 mentions) Ifn α, by Abcam (1 mentions) Il 12, by Thermo Fisher Scientific (1 mentions) Ifn γ, by BioLegend (1 mentions) Ifn γ, by R&D Systems (1 mentions) Ifn γ, by BD (1 mentions) Il 12, by R&D Systems (1 mentions) Pam3cys, by Merck Group (1 mentions) Dexamethasone (dex), by Selleck Chemicals (1 mentions) Ritlecitinib, by MedChemExpress (1 mentions) Tofacitinib, by MedChemExpress (1 mentions) Ruxolitinib, by Selleck Chemicals (1 mentions) Fedratinib, by MedChemExpress (1 mentions) Anti cd28, by Thermo Fisher Scientific (1 mentions) Anti cd3, by Thermo Fisher Scientific (1 mentions) Ruxolitinib, by Novartis (1 mentions) Tofacitinib, by Pfizer (1 mentions)

5 protocols using upadacitinib

1

Human MDMs Cytokine Response to Stimuli

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human MDMs were treated with lipid A (Peptides International, Louisville, KY), Pam3Cys (EMD Millipore, Billerica, MA), polyinosinic-polycytidylic acid [poly(I:C)], CpG DNA (Invivogen, San Diego, CA), IL-12, IFN-γ (R&D Systems, Minneapolis, MN), IFN-α (Biovision, Milpitas, CA), or cocultured with Salmonella enterica serovar Typhimurium at multiplicity of infection (MOI) 10:1. Supernatants were assayed for IL-6, IL-10, TNF, IL-1β, IFN-γ (BD Biosciences), IL-12 (eBioscience, San Diego, CA), or IFN-γ (BioLegend) by ELISA. In some cases, cells were pretreated with 5 μg/ml fludarabine (STAT1 inhibitor), 150 μM lisofylline (STAT4 inhibitor) (Cayman Chemical Company), Upadacitinib (JAK1 inhibitor), or BMS-986165 (TYK2 inhibitor) (MedChemExpress).
Hedl M., Sun R, & Abraham C. (2020). Disease Risk-Associated Genetic Variants in STAT1 and STAT4 Function in a Complementary Manner to Increase Pattern-Recognition Receptor–Induced Outcomes in Human Macrophages. Journal of immunology (Baltimore, Md. : 1950), 205(5), 1406-1418.
+ Open protocol
+ Expand
2

Inhibition of IFN-γ production by NK-92 cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human NK-92 cells were analyzed for their ability to produce IFN-γ upon incubation with different small-molecule inhibitors. Baricitinib (HY-15315), Tofacitinib (HY-40354), Upadacitinib (HY-19569), and Ritlecitinib (HY-100754) were purchased from MedChemExpress LLC. Ruxolitinib (S1378) and Dexamethasone (S1322) were purchased from Selleckchem. NK-92 cells were initially starved for 4 h in plain RPMI medium. Cells were then resuspended at a density of 1 × 106 cells/mL in complete RPMI, and 100 μL of the cell suspension was incubated with increasing concentrations of the inhibitors (up to 3 µM) in the presence of L19-IL12 (10 ng/mL). After 24 h, cell-free supernatants were collected, and the concentration of IFN-γ was measured using the ELISA MAXTM Set Human IFN-γ kit (BioLegend).
Rotta G., Gilardoni E., Ravazza D., Mock J., Seehusen F., Elsayed A., Puca E., De Luca R., Pellegrino C., Look T., Weiss T., Manz M.G., Halin C., Neri D, & Dakhel Plaza S. (2024). A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors. EMBO Molecular Medicine, 16(4), 904-926.
+ Open protocol
+ Expand
3

Cytokine-Induced T Cell Activation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant human IL-6 and IFN gamma (both carrier-free, Biolegend, London) and anti-CD3 and anti-CD28 (both Thermo Fisher Scientific, Germany) were used for in vitro stimulation. JAK inhibitors baricitinib, upadacitinib, and fedratinib were purchased from MedChemExpress (NJ).
Dold L., Frank L., Lutz P., Kaczmarek D.J., Krämer B., Nattermann J., Weismüller T.J., Branchi V., Toma M., Gonzalez-Carmona M., Strassburg C.P., Spengler U, & Langhans B. (2023). IL-6–Dependent STAT3 Activation and Induction of Proinflammatory Cytokines in Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 14(8), e00603.
+ Open protocol
+ Expand
4

JAK Inhibitor Effects on B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats or EDTA blood by density gradient centrifugation. Total or CD27+ B cells were isolated magnetically using EasySep isolation kits (Human B-cell Isolation Kit/CD27+ B-cell Isolation Kit (Stemcell Technologies)) following the manufacturers’ instructions. B cells were plated in 96-well plates with 30.000 cells/well in Iscove’s Modified Dulbecco’s Medium (Life Technologies) supplemented with 10% FCS, insulin, apo-transferrin, non-essential amino acids, glutamine and glutathione as described previously (20 (link)) and stimulated with CpG (ODN2009, Apara Biosciences) at a concentration of 0.5µM. Baricitinib (Toronto Research Chemicals), tofacitinib (provided by Pfizer Inc, Peaback, USA), ruxolitinib (Novartis), upadacitinib (ABT-494, MedChemExpress), filgotinib (GLPG0634, selleckchem) were stored as 10nM stocks in dimethylsulfoxide and further diluted in medium as needed. JAK inhibitors were added to indicated samples at doses of 10-3000nM.
Frede N., Lorenzetti R., Hüppe J.M., Janowska I., Troilo A., Schleyer M.T., Venhoff A.C., Voll R.E., Thiel J., Venhoff N, & Rizzi M. (2023). JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis. Frontiers in Immunology, 14, 1087986.
+ Open protocol
+ Expand
5

Small Molecule Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
All reagents and solvents were purchased from Thermo Fischer or Sigma-Aldrich and used as received. Small molecules (LCL-161 (1), R848 (2), Ruxolitinib (3), Upadacitinib (4), BP-1-102 (5), STX-0119 (6)) were purchased from MedChem Express, dissolved in DMSO accordingly and used without any further purification. MilliQ water was obtained from the Waters filtration system.
Harrod R, & Lovett P.S. (1995). Peptide inhibitors of peptidyltransferase alter the conformation of domains IV and V of large subunit rRNA: a model for nascent peptide control of translation.. Proceedings of the National Academy of Sciences of the United States of America, 92(19), 8650-8654.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!